Research guide · Recovery & Repair
Thymosin Alpha-1 — research protocol
Immune-modulating peptide studied for natural defense and recovery studies.
This guide summarizes study areas and sources associated with the compound. BioPeptideX does not convert experimental information into a clinical regimen or recommend an individual dose, frequency, route or duration.
Catalog presentations
Concentration table
Mathematical reference only; this is not a dosing recommendation.
Research areas
- Immunomodulator
- 28-amino-acid peptide
- Sealed lyophilized form
Most-cited research protocols
Educational information based on research protocols and literature; it does not replace guidance from a healthcare professional.
Thymosin Alpha-1 (TA1) is a 28-amino-acid peptide that helps train and coordinate immune cells. The synthetic version, thymalfasin (Zadaxin), is approved in over 35 countries for chronic hepatitis B, chronic hepatitis C, and as an immune adjunct in cancer care.
| Dose | Frequency | Duration | Route | |
|---|---|---|---|---|
| Standard adult dosing | 1.6 mg | Twice weekly | 6 months (HBV monotherapy / cancer adjunct); up to 12 months (HCV combination) | Subcutaneous |
| Body-weight-adjusted dosing (under 40 kg) | 40 mcg/kg | Twice weekly | Not specified for this protocol | Subcutaneous |
Cycle: Cycle lengths reported from research vary by context: 6 months for chronic hepatitis B, 6-12 months for chronic hepatitis C, and 7 days continuous for severe sepsis.
Benefits and research observations: Clinical changes in lymphocyte/CD4+ levels are typically observed within 4-8 weeks, while viral load reduction (HBV) may take 12-26 weeks. Sustained viral response (HCV) can be measured up to 12 months post-treatment.
Handling and storage
Store unreconstituted product according to its label and maintain the cold chain where applicable. After any preparation, follow only validated instructions for the specific product and diluent. Do not use if packaging is damaged or the solution shows particles or unexpected changes.
Warnings
Do not use this page for self-diagnosis or self-medication. Pregnancy, breastfeeding, minors, cancer history, allergies, active disease and concurrent treatments require individual professional evaluation.
Published sources
- 1.Goldstein AL, et al. Ann NY Acad Sci, 2010.
- 2.King R, Tuthill C. Vitam Horm, 2016.